Long-term outcome from a study on the prevention of postoperative recurrence in patients with renal cell carcinoma: Could PBL be a predictor of postoperative recurrence in patients postoperatively treated with IFN-γ?

Acta Urologica Japonica

Volumn 52, Issue 8, 2006, Pages 603-608

  Kawata, Nozomu ^a   Ichinose, Taketo ^a   Hachiya, Takahiko ^a   Hirakata, Hitoshi ^a   Igarashi, Takumi ^a   Nagane, Yusuke ^a   Morita, Koutaro ^a   Takimoto, Yukie ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Interferon ; PBL; Postoperative recurrence; Renal cell carcinoma

Indexed keywords

CD11 ANTIGEN; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; KIDNEY CARCINOMA; LYMPHOCYTE; MALE; NEPHRECTOMY; POSTOPERATIVE PERIOD; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 33748943976     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Nanus DM, Pfeffer LM, Barder NH, et al.: Anti proliferative and antitumor effect of alfa-interferon in RCC: correlation to the expression of a kidney-associated differentiation glycoprotein. Cancer Res 50: 4190-4194, 1990
2. Czarniecki CW, Fennie CW, Powers DB, et al.: Synergistic antiviral and antiproliferative activations of E. coli derived from alfa, beta, and gamma interferons. J Virol 49: 490-496, 1984
3. Aulitzky WE, Aulitzky W, Ellerhorst J, et al.: Intermittent low-dose IFN gamma treatment for metastatic renal cell carcinoma: analysis of factors predicting clinical response and long-term survival. Onkologie 18: 339-345, 1995
4. Bulowski RM: Natural history and therapy of metastatic renal cell carcinoma: the role of IL-2. Cancer 80: 1198-1220, 1997
5. Levy DA, Slaton JW, Swanson DA, et al.: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159: 1163-1167, 1998
6. rd ed. pp 67-73, Kenehara. Tokyo, 1999
7. Grups JW and Frohmuller HGW: Influence of cyclic interferon gamma on lymphocytes and their subpopulations in patients with renal carcinoma. Urology 35: 111-114, 1990
8. Aulitzky WE, Aulitzky W, Gastl G, et al.: Acute effects of single doses of recombinant Interferon-γ on blood cell counts lymphocytes in patients with advanced RCC. J Interferon Res 9: 425-433, 1989
9. Kawata N, Takimoto Y, Kodama M, et al.: Multivariate analysis of clinicopathological factors and the efficacy of postoperative IFN-γ adjuvant therapy in 115 patients with renal cell carcinoma. Int J Clin Oncol 4: 164-169, 1999
10. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
11. Firth, D: Bias reduction of maximum likelihood estimates. Biometrika 80: 27-38, 1993
12. Robson CJ, Churchill BM and Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297-301, 1969
13. Guinan PD, Vogelzang NJ, Fremgen AM et al.: Renal cell carcinoma tumor size, stage and survival. J Urol 153: 901-903, 1995
14. Skinner DG, Colvin RB, Vermillion CD, et al.: Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 28: 1165-1177, 1971
15. Minervini A, Lilas L, Minervini R, et al.: Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma, long term analysis in 213 patients. Cancer 94: 2590-2595, 2002
16. Palmer PA, Vinke J, Philip T, et al.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475-480, 1992
17. Takahashi S, Tanigawa T, Imagawa M, et al.: Interferon as adjunctive treatment for non-metastatic renal cell carcinoma. Br J Urol 74: 11-14, 1994
18. Migliari R, Muscas G, Solinas A, et al.: Is there a role for adjuvant immunotherapy after radical nephrectomy in pT2-3 N0M0 renal cell carcinoma. J Chemother 7: 240-245, 1995
19. Arima K, Nakagawa M, Yanagawa M, et al.: Prognostic factors of peripheral blood lymphocyte subsets in patients with renal cell carcinoma. Urol Int 57: 5-10, 1996
20. Characiejus D, Pasukoniene V, Kazlauskaite N, et al.: Predictive value of CD8 high CD57+ lymphocytes subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22: 3679-3684, 2002
21. Barna BP, Thomassen MJ, Sergi J, et al.: Immunologic changes in renal cell carcinoma patients receiving gamma interferon. Oncology 48: 464-468, 1991
22. Kawata N, Yagasaki H, Yuge H, et al.: Histopathological analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment. Int J Urol 8: 275-281, 2001
23. Mcfarland HI, Nahill SR, Maciaszek JW, et al.: CD11b (Mac-1): A marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol 149: 1326-1333, 1992
24. Momose T, Okubo Y, Horie S, et al.: Interferon-γ increases CD62L expression on human eosinophils. Int Arch Allergy Immunol 120: 30-33, 1999